Companies

Targeted protein degradation (TPD) companies, sorted by competitive overlap with Kymera Therapeutics. Includes pipeline programs, clinical phase, and disease area focus.

Featured case study

Primary companyNASDAQ: KYMR

Kymera Therapeutics

Pioneering targeted protein degradation: oral small molecules that destroy disease-causing proteins instead of blocking them. The only company with clinical-stage PROTAC programs spanning immunology (STAT6, IRAK4, IRF5) and oncology (CDK2 glue).

Full profile

Pipeline programs

KT-621STAT6Atopic Dermatitis / Asthma

Immunology2b

KT-485IRAK4Hidradenitis Suppurativa / AD

ImmunologyPh 2

KT-579IRF5Lupus / Sjögren's / RA

ImmunologyPh 1

CDK2 GlueCDK2CCNE1-amplified Breast Cancer

OncologyIND

Pegasus™ Platform · $979M cash · Sanofi ($2.1B) + Gilead partnerships

TPD landscape →

Competitive landscape

Sorted by therapeutic area overlap and clinical stage

Full TPD matrix

ImmunologyOncologyNeurology6 companies

Arvinas

ARVN

Ph 3

OncologyNeurology

PROTAC® Technology · 3 clinical programs

ARV-471 (Vepdegestrant)·ER+/HER2- Breast CancerPh 3

ARV-110 (Bavdegalutamide)·Metastatic Castration-Resistant Prostate CancerPh 2

ARV-102·Parkinson's DiseasePh 1

arvinas.com TPD landscape

C4 Therapeutics

CCCC

1/2

Oncology

TORPEDO® · 3 clinical programs

CFT8919·EGFR L858R NSCLC1/2

CFT1946·BRAF V600X Solid TumorsPh 1

CFT7455·Relapsed/Refractory MM / NHL1/2

c4therapeutics.com TPD landscape

Nurix Therapeutics

NRIX

Ph 1

Oncology

DELigase™ · 2 clinical programs

NX-5948·B-cell Malignancies / CLL / MCLPh 1

NX-2127·Relapsed/Refractory B-cell MalignanciesPh 1

nurixtx.com TPD landscape

Monte Rosa Therapeutics

GLUE

Ph 1

Oncology

QuEEN® · 2 clinical programs

MRT-2359·MYC-Driven Cancers (NSCLC, SCLC)Ph 1

MGX-12·Solid Tumors (Treg depletion)Ph 1

monterosatx.com TPD landscape

Plexium

Private

Ph 1

Oncology

Molecular Glue Discovery · 1 clinical program

PLX-4545·Solid TumorsPh 1

plexium.com TPD landscape

Vividion Therapeutics

Bayer (2021)

Pre

Oncology

Chemoproteomics-guided TPD · 0 clinical programs

VVD-159·OncologyPre

vividion.com TPD landscape

Data sources:Company investor materialsClinicalTrials.govSEC filingsPress releasesInteractive TPD matrix